nach oben

Applied Health Economics and Health Policy

Erschienen in:

01.04.2013 | Original Research Article

Annual All-Cause Healthcare Costs Among Influenza Patients With and Without Influenza-Related Complications

Analysis of a United States Managed Care Database

verfasst von: Sudeep Karve, Derek Misurski, Guillermo Herrera-Taracena, Keith L. Davis

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Several studies have reported that patients with influenza have a high risk of developing complications such as secondary infections, exacerbation of cardiovascular conditions and asthma. However, limited data exists on the healthcare cost burden for influenza patients with and without influenza-related complications.

Objective

We compared healthcare utilization and costs among influenza patients with related complications versus patients without complications.

Methods

In this retrospective database analysis (LifeLink database: 1998–2009) of a US managed care database, we selected patients diagnosed with influenza during influenza seasons and categorized them as complicated or uncomplicated based on the presence or absence of a diagnosis for a related complication in the year following their influenza diagnosis. Multivariable regression analyses were conducted to compare all-cause utilization and costs (adjusted to 2009 US dollars) between the two groups.

Results

We identified 54,469 patients of which ~65 % had evidence for at least one complication. Patients with complicated influenza had a 1.5-fold higher rate of inpatient utilization compared with uncomplicated cases (p < 0.001). Significantly higher covariate-adjusted predicted mean annual costs were also observed among complicated influenza patients across all care (p-values <0.001 for all comparisons).

Conclusion

Healthcare costs were twice as high among influenza patients with complications versus those without, with inpatient and outpatient services being the primary cost drivers. Now with the universal recommendation for seasonal influenza vaccination for all individuals ≥6 months of age, improvement in coverage rates may help reduce the healthcare utilization and costs associated with influenza and associated complications.

Nur mit Berechtigung zugänglich

Centers for Disease Control and Prevention. Seasonal influenza. 2011. http://www.cdc.gov/flu/about/qa/disease.htm. Accessed 18 Oct 2012.

Centers for Disease Control and Prevention (CDC). Interim results: state-specific seasonal influenza vaccination coverage—United States, August 2009–January 2010. MMWR Morb Mortal Wkly Rep. 2010;59(16):477–84.

Fiore AE, Uyeki TM, Broder K, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1–62.PubMed

Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics. 2000;106(5):973–6.PubMedCrossRef

Esposito S, Marchisio P, Bosis S, et al. Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine. 2006;24(5):629–35.PubMedCrossRef

Nichol KL, D’Heilly S, Ehlinger EP. Influenza vaccination among college and university students: impact on influenzalike illness, health care use, and impaired school performance. Arch Pediatr Adolesc Med. 2008;162(12):1113–8.PubMedCrossRef

Nichol KL, D’Heilly SJ, Greenberg ME, et al. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50–64 years. Clin Infect Dis. 2009;48(3):292–8.PubMedCrossRef

Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322–32.PubMedCrossRef

Ryan J, Zoellner Y, Gradl B, et al. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine. 2006;24(47–48):6812–22.PubMedCrossRef

10.

Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26(11):911–24.PubMedCrossRef

11.

Li S, Leader S. Economic burden and absenteeism from influenza-like illness in healthy households with children (5–17 years) in the US. Respir Med. 2007;101(6):1244–50.PubMedCrossRef

12.

Menec VH, Black C, MacWilliam L, et al. The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality. Can J Public Health. 2003;94(1):59–63.PubMed

13.

Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–96.PubMedCrossRef

14.

Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002;156(10):986–91.PubMedCrossRef

15.

Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–40.PubMedCrossRef

16.

Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR Morb Mortal Wkly Rep 2010b;59:1057–62.

17.

Cox F, Khan ZM, Schweinle JE, et al. Cost associated with the treatment of influenza in a managed care setting. MedGenMed. 2000;2(4):E34.PubMed

18.

Irwin DE, Weatherby LB, Huang WY, et al. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res. 2001;1:8.PubMedCentralPubMedCrossRef

19.

Loughlin J, Poulios N, Napalkov P, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics. 2003;21(4):273–83.PubMedCrossRef

20.

Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med. 2010;38(4 Suppl.):e91–7.PubMedCrossRef

21.

Toschke AM, Heuschmann PU, Wood O, et al. Temporal relationship between influenza infections and subsequent first-ever stroke incidence. Age Ageing. 2009;38(1):100–3.PubMedCrossRef

22.

Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics. 2006;118(6):2409–17.PubMedCrossRef

23.

Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–13.PubMedCentralPubMedCrossRef

24.

Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161(3):441–6.PubMedCrossRef

25.

Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med. 2010;38(4 Suppl.):e91–7.PubMedCrossRef

26.

Ruf BR, Szucs T. Reducing the burden of influenza-associated complications with antiviral therapy. Infection. 2009;37(3):186–96.PubMedCrossRef

27.

Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–83.PubMedCrossRef

28.

Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.PubMedCrossRef

29.

Lee WC, Hoffmann MS, Arcona S, et al. A cost comparison of alternative regimens for treatment-refractory partial seizure disorder: an econometric analysis. Clin Ther. 2005;27(10):1629–38.PubMedCrossRef

30.

Mucha L, Shaohung S, Cuffel B, et al. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer’s disease. J Manag Care Pharm. 2008;14(5):451–61.PubMed

31.

Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.PubMedCrossRef

32.

Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care. 2006;12(2):110–9.PubMed

33.

Perkins AJ, Kroenke K, Unützer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol. 2004;57(10):1040–8.PubMedCrossRef

34.

Holder KA, Clark SL. Working beyond retirement-age. U.S. Census Bureau. Housing and Household Economic Statistics Division Labor Force Statistics Branch, 2008.

35.

Maciosek MV, Solberg LI, Coffield AB, et al. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. 2006;31(1):72–9.PubMedCrossRef

36.

Strikasa RA, Bridgesb CB, Singleton JA. Influenza vaccination recommended for all adults aged 50 years and older, United States. Int Congr Ser. 2001;1219:665–9.CrossRef

37.

Fiore AE, Shay DK, Broder K, et al. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-8):1–52.

38.

Milenkovic M, Russo CA, Elixhauser A. Hospital stays for influenza, 2004: Statistical brief #16. Healthcare cost and utilization project (HCUP) statistical briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2013. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb16.pdf. Accessed 27 Feb 2013.

39.

Monto AS. Seasonal influenza and vaccination coverage. Vaccine. 2010;28(Suppl. 4):D33–44.PubMedCrossRef

40.

Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58(6):446–58.PubMedCrossRef

Titel: Annual All-Cause Healthcare Costs Among Influenza Patients With and Without Influenza-Related Complications
Analysis of a United States Managed Care Database
verfasst von: Sudeep Karve
Derek Misurski
Guillermo Herrera-Taracena
Keith L. Davis
Publikationsdatum: 01.04.2013
Verlag: Springer International Publishing
Erschienen in: Applied Health Economics and Health Policy / Ausgabe 2/2013
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI: https://doi.org/10.1007/s40258-013-0020-6

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases

Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments

The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia

Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients

Is it Financially Efficient to Lose the Ring-Fenced Elective Orthopaedic Ward?

Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma